Search Immortality Topics:

Page 10«..9101112..2030..»


Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Posted: January 20, 2021 at 1:13 am

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Read more here:
Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Recommendation and review posted by Fredricko

Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters

Posted: January 20, 2021 at 1:13 am

NEW YORK, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it is constructing a Product Showroom (“Showroom”) inside its new corporate headquarters.  The Company has made this decision in anticipation of and in preparation for important future Agreement(s) & Partnership(s).  The Company expects to host a broad array of prospective new customers, once this Showroom is functional.  These potential new customers include, but are not limited to: Individual Customers, Mom & Pop Stores, Gas Station Convenience Stores, Large Regional & National Retailers, Major Distributors, and College Campus Stores.

More:
Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters

Recommendation and review posted by Fredricko

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Posted: January 20, 2021 at 1:13 am

President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20 President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20

Read this article:
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Recommendation and review posted by Fredricko

VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates)

Posted: January 20, 2021 at 1:13 am

1 Growth at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year, and by excluding sales of Sentinel for the two financial years in question.

Originally posted here:
VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates)

Recommendation and review posted by Fredricko

Agenus to Participate in B. Riley Securities’ Oncology Investor Conference

Posted: January 20, 2021 at 1:13 am

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Steven O’Day, CMO of Agenus, will participate in B. Riley Securities’ Oncology Investor Conference on January 20-21, 2021.

See the rest here:
Agenus to Participate in B. Riley Securities' Oncology Investor Conference

Recommendation and review posted by Fredricko

Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

Posted: January 20, 2021 at 1:13 am

Owen Wallace to Transition to Scientific Advisory Board Owen Wallace to Transition to Scientific Advisory Board

Here is the original post:
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

Recommendation and review posted by Fredricko


Page 10«..9101112..2030..»